Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled date : 2021 - 06 - 01 save search
AquaBounty Announces First Harvest of GE Atlantic Salmon; Receives Approval for the Sale of GE Atlantic Salmon in Brazil
Published: 2021-06-01 (Crawled : 21:00) - globenewswire.com
AQB | $1.72 -1.71% -1.74% 16K
|
Health Technology
|
| O: 1.69%
H: 0.5%
C: -3.17%
brazil approval
Photon Control Announces the Mailing of its Management Information Circular in Connection with its Annual and Special Meeting to Approve Acquisition by MKS Instruments
Published: 2021-06-01 (Crawled : 21:00) - globenewswire.com
MKSI | $108.1 -3.56% -3.69% 770K
|
Electronic Technology
|
| O: -0.02%
H: 1.07%
C: 0.47%
acquisition
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Published: 2021-06-01 (Crawled : 21:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.85%
H: 0.37%
C: 0.02%
treatment fda fda approval children approval psoriasis plague
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Published: 2021-06-01 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.53%
H: 0.03%
C: -2.72%
treatment fda therapy breakthrough therapy grant designation
Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated
Published: 2021-06-01 (Crawled : 12:00) - biospace.com/
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 4.06%
H: 3.76%
C: 2.79%
initiated approval eflapegrastim
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Published: 2021-06-01 (Crawled : 12:00) - globenewswire.com
PRTK | $2.23 0.0% 4.8M
|
Health Technology
|
| O: 6.48%
H: 12.99%
C: 12.3%
treatment fda acquired fda approval approval
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2021-06-01 (Crawled : 11:00) - investor.alkermes.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.29%
H: 0.28%
C: -0.95%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.79%
H: 1.4%
C: 1.31%
treatment fda schizophrenia fda approval approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.